Vycor Medical Posts Mixed Q3 2026 Results as VBAS Clinical Evidence Mounts

Vycor Medical's Q3 2026 revenue fell 19% on tough prior-year comparisons, but continued operating profitability and four new peer-reviewed VBAS studies underscore the device's growing clinical validation and long-term market potential.

Chicago Metrowire Staff
••Healthcare
Vycor Medical Posts Mixed Q3 2026 Results as VBAS Clinical Evidence Mounts

Vycor Medical, Inc. (OTCQB: VYCO) reported financial results for the three and nine months ended September 30, 2026, revealing a revenue decline that the company attributes largely to unusually high U.S. sales in the prior-year period. Total revenue for the third quarter fell 19% to $414,895, while nine-month revenue decreased 11% to $1,291,699. The Vycor Medical division, which produces the ViewSite Brain Access System (VBAS) for neurosurgeons, saw third-quarter revenue drop 18% to $402,048, and nine-month revenue decline 11% to $1,243,713. Management noted that the 2025 period benefited from new hospitals and bulk orders from existing hospitals, and that international sales can be uneven as large orders sometimes fall in different quarters.

Despite the top-line pressure, the company maintained operating profitability. GAAP operating profit was $27,424 for the third quarter and $80,083 for the nine-month period, compared with $32,085 and $70,425 in 2025, respectively. Non-GAAP operating profit, which excludes non-cash depreciation and stock-based compensation, was $43,011 for the quarter and $125,751 for the nine months. Gross margin remained strong at 85% for the quarter and 83% for the nine months, though slightly below prior-year levels. The NovaVision division, still in development, posted a 41% increase in third-quarter revenue to $12,847 and an 11% increase for the nine months to $47,986, signaling early traction for its vision rehabilitation therapies.

The most significant development for Vycor's long-term prospects may be the continued accumulation of clinical evidence for VBAS. During 2026, four new peer-reviewed studies were published on the device, bringing the total to 54 peer-reviewed clinical papers plus 14 other clinical papers. These studies reinforce the device's value proposition: a case study on a complex pediatric tumor highlighted VBAS combined with neuro-navigation as a paramount strategy for surgical resection; a retrospective study of 23 patients found significantly fewer new neurological deficits with VBAS compared to traditional blade retractors; a single-center study of 29 adults demonstrated effective decompression of posterior fossa metastases with low cerebrospinal fluid diversion rates; and a Japanese report on two intracerebral hemorrhage cases showed VBAS provided a stable corridor for deep hemostasis using familiar microsurgical instruments. For a company seeking to expand adoption in neurosurgery, this growing body of evidence is critical to convincing surgeons and hospital administrators of the device's safety and efficacy.

Vycor's dual-business structure also offers diversification. The VBAS system is already approved and used in over 350 U.S. hospitals and numerous international markets, protected by 49 issued and 8 pending patents. NovaVision's Visual Restoration Therapy is the only commercialized FDA-cleared therapy for vision rehabilitation following neurological brain damage, and its NeuroEyeCoach program has demonstrated improvement in over 80% of patients in a 296-patient study. While NovaVision remains a development-stage business requiring significant investment, its unique regulatory position could provide a future growth engine.

For investors, the key takeaway is that Vycor remains operationally profitable on a non-GAAP basis despite revenue volatility, while its clinical pipeline and patent estate strengthen its competitive moat. The company's ability to grow international sales and advance NovaVision toward commercialization will determine whether it can return to sustained revenue growth. More information is available at www.vycormedical.com, www.vycorvbas.com, and www.novavision.com, and overviews of the technologies can be viewed in the VBAS Video and NovaVision Video.

Blockchain Registration

QR Code for Blockchain Registration